Kolon Life Science announced on the 27th that it held a shareholders' meeting and a board of directors meeting on the 26th, appointing Executive Vice President Lee Hanguk as the new CEO.


Born in 1973, the new CEO, Lee Hanguk, is an expert in the pharmaceutical and biotech industries, with comprehensive experience throughout the entire process of developing and commercializing new drugs, generics, and active pharmaceutical ingredients, spanning research and development, manufacturing, regulatory affairs, and domestic as well as global business development.


Lee Hanguk, new CEO of Kolon Life Science. Kolon Life Science

Lee Hanguk, new CEO of Kolon Life Science. Kolon Life Science

View original image

CEO Lee was previously responsible for synthetic research, overseas regulatory affairs, international business, and the establishment of overseas research hubs at Daewoong Pharmaceutical. He also served as an executive in the RA division at a biotech company in San Diego, USA. Afterward, he moved to Gunil Pharmaceutical, where he served as CEO after leading the medical and R&D divisions. During his tenure, he maximized profitability and business performance by expanding international business and securing manufacturing capabilities for overseas expansion.


Kolon Life Science stated, "We appointed Lee Hanguk as the new CEO for his expertise in executing regulatory strategies in the global market and his ability to organically connect development, manufacturing, regulatory affairs, and commercialization."


Lee Hanguk, the new CEO of Kolon Life Science, commented, "Based on Kolon Life Science's outstanding bio and chemical capabilities, I will build new trust in the global bio market and deliver visible results."



Kolon Life Science plans to accelerate achievements in its bio division by focusing on key gene therapy pipelines such as KLS-3021 and KLS-2031, while also advancing its two-track growth strategy by expanding the supply of precision chemical materials and active pharmaceutical ingredients and refining its electronic materials portfolio in the chemical division.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing